[Application and limitation of neoadjuvant hormonal therapy for prostate cancer].
Of 156 patients, 111 (clinical stage T1a-b; 21, T1c; 17, T2a-b; 36, T2c; 27, T3; 10) immediately underwent radical prostatectomy (surgery group), and 45 (clinical stage T1a-b; 8, T1c; 4, T2a-b; 10, T2c; 9, T3; 14) received neoadjuvant hormonal therapy (NHT group). NHT offered probability of increasing organ-confined cancer(OCC; pathological stage pT2 or lower N0M0) in the following group, which contains (a) patients who had moderately differentiated adenocarcinoma in the biopsy specimen and T2b or lower diseases, and (b) those who had well differentiated adenocarcinoma, T2c diseases and PSA levels of 10 ng/ml or higher, referred to as "OCC suitable criteria". Of 156 patients, 51 (33%) met OCC suitable criteria. In those cases, the proportion of OCC in NHT group was significantly higher than that in surgery group (11/12 (92%) vs. 16/39 (41%), p = 0.002). NHT is useful for increasing OCC in patients who meet OCC suitable criteria.
Demura
T
T
Dept. of Urology, Hokkaido University School of Medicine.
Shinohara
N
N
Nonomura
K
K
Koyanagi
T
T
D000230:Adenocarcinoma / Q000628:therapy*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000628:therapy*
D018931:Antineoplastic Agents, Hormonal